Aldoxorubicin
- Generic Name
- Aldoxorubicin
- Drug Type
- Small Molecule
- Chemical Formula
- C37H42N4O13
- CAS Number
- 1361644-26-9
- Unique Ingredient Identifier
- C28MV4IM0B
- Background
Aldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.
- Indication
Investigated for use/treatment in solid tumors.
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 328
- Registration Number
- NCT04390399
- Locations
- 🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States
🇺🇸Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
🇺🇸Hoag memorial Presbyterian Hospital, Newport Beach, California, United States
QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.
- Conditions
- ChordomaUnresectable Malignant Neoplasm
- Interventions
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03647423
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.080: NANT Pancreatic Cancer Vaccine
- Conditions
- Pancreatic Cancer
- Interventions
- Biological: ALT-803Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for infusionBiological: bevacizumabBiological: AvelumabProcedure: SBRT
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03586869
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03574649
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.088: NANT Pancreatic Cancer Vaccine
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03563144
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine
- Conditions
- mCRCColorectal Cancer Metastatic
- Interventions
- Procedure: SBRT
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03563157
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine
- Conditions
- Triple Negative Breast Cancer (TNBC)
- Interventions
- First Posted Date
- 2018-06-12
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03554109
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Biological: N-803Biological: ETBX-011Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for InfusionBiological: avelumabBiological: bevacizumabProcedure: SBRT
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT03387085
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed
- Conditions
- Squamous Cell Carcinoma
- Interventions
- Biological: ETBX-011Biological: ETBX-021Biological: ETBX-051Biological: ETBX-061Biological: GI-4000Biological: GI-6207Biological: GI-6301Biological: haNK for infusionProcedure: SBRTBiological: N-803
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03387111
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
- Conditions
- Pancreatic Cancer
- Interventions
- Biological: ALT-803Biological: ETBX-011Biological: GI-4000Biological: haNK for infusionBiological: avelumabBiological: bevacizumabProcedure: SBRT
- First Posted Date
- 2017-12-29
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- ImmunityBio, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03387098
- Locations
- 🇺🇸
Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.